GlassScriptPhysician profile
David F Camara
NPI 1437110749
$906.35
in general payments reported to CMS, 2019-2025
12 companies · $86.37 in 2025
The $86.37 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $80.01 · 2021: $184 · 2022: $72.90 · 2023: $19.86 · 2024: $102 · 2025: $86.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $190 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.03 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $167.04 | 2019-2024 | Cequa |
| Shire North American Group INC | $165.39 | 2019 | |
| Ivantis, INC | $135.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $129.27 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $61.70 | 2022-2024 | Miebo, Xiidra |
| Alcon Vision LLC | $48.27 | 2019-2025 | Rocklatan |
| Allergan, INC. | $44.69 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $43.86 | 2019-2025 | Tecnis Iol |
| Thea Pharma INC. | $39.92 | 2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $32.95 | 2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $24.45 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Camara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.